The bill adds Section 409K to the Public Health Service Act to establish the Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE) Initiative at the National Institutes of Health. The Initiative directs the NIH Director to run a coordinated research program focused on reducing preventable maternal deaths and severe maternal morbidity, narrowing disparities, and improving health for pregnant and postpartum women before, during, and after pregnancy.
Operationally, the statute instructs NIH to pursue an integrated research approach—examining biological, behavioral, and other drivers of maternal outcomes—prioritize building region‑specific evidence, and support implementation and evaluation of community‑based interventions for populations with disproportionately high rates of maternal mortality and morbidity. The Director may use grants, contracts, cooperative agreements, or other transactions; Congress has authorized $73,400,000 per year for fiscal years 2026 through 2031 to carry out the Initiative (subject to appropriations).
At a Glance
What It Does
Creates the IMPROVE Initiative within NIH (added as Sec. 409K of the PHS Act) to fund research and evaluated community interventions addressing maternal mortality, severe maternal morbidity, and related disparities. The Director may award grants, contracts, cooperative agreements, or other transactions to implement the program.
Who It Affects
Academic researchers, NIH institutes and centers, public health departments, community‑based organizations that deliver maternal health programs, and health systems in specified regions with high maternal risk. Federally funded research infrastructure and grant administrators will see new programmatic activity and funding opportunities.
Why It Matters
It directs sustained federal research dollars to maternal health with an explicit equity mandate and regional focus, creating a new bucket of NIH support for translational and community‑centered work that could change how maternal‑health interventions are developed, tested, and scaled.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill formally creates the IMPROVE Initiative inside the NIH by adding a new statutory section. That section sets three linked goals: lower preventable maternal death and severe complications, shrink disparities in maternal outcomes across disproportionately affected populations, and improve health across the pregnancy lifecycle.
The language ties these goals together under a single research and implementation program run by the NIH Director.
Rather than prescribe a single method, the statute requires an integrated research approach. NIH is to support studies that combine biological, behavioral, and other lines of inquiry and to build an evidence base targeted to particular U.S. regions.
The bill also directs the Initiative to both implement and evaluate community‑based interventions—so funding is intended for research plus practical, local programs designed to change outcomes.For implementation, the Director gets broad authority to fund work using grants, contracts, cooperative agreements, or ‘‘other transactions’’—a flexible contracting tool NIH has used for public‑private or nontraditional research partnerships. The law authorizes a specific funding level: $73.4 million annually for fiscal years 2026 through 2031.
That is an authorization, not an appropriation; actual funding will depend on subsequent congressional action.Notably, the statute is light on procedural prescriptions: it does not define the disproportionately affected populations, set criteria for region selection, mandate specific metrics or reporting timelines, or impose cross‑agency governance. Those implementation choices will be left to NIH rulemaking, program notices, and grant terms, which will determine how the statute’s broad goals are translated into funded projects and measurable outcomes.
The Five Things You Need to Know
Section 409K adds the IMPROVE Initiative to the Public Health Service Act and directs the NIH Director to continue and operate the program focused on maternal health outcomes.
The Initiative’s three statutory objectives are: reduce preventable maternal mortality and severe maternal morbidity; reduce disparities tied to populations with disproportionately high rates; and improve health before, during, and after pregnancy.
The statute requires an integrated research approach that explicitly includes biological, behavioral, and other factors and mandates building region‑specific evidence bases.
The Director may award support via grants, contracts, cooperative agreements, or other transactions—granting NIH flexibility to use nonstandard contracting vehicles for research and community partnerships.
The law authorizes $73,400,000 per year to carry out the Initiative for fiscal years 2026 through 2031; funding remains subject to the annual appropriations process.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title and placement in statute
The bill provides the program’s short title (NIH IMPROVE Act) and locates the new authority in Part B of Title IV of the PHS Act. That placement makes the Initiative an explicit, codified NIH program rather than a temporary appropriation rider, which can affect how it is referenced in future legislation and budget documents.
Program establishment and executive responsibility
Subsection (a) tasks the NIH Director with carrying out the Initiative. Practically, this creates a single leadership locus inside NIH accountable for program design, funding solicitations, and coordination across NIH institutes and centers. Calling for continuation of a program gives NIH discretion to structure the Initiative within existing institutes or as cross‑cutting activities, but it also places operational responsibility squarely with the Director.
Statutory objectives and research focus
Subsection (b) enumerates the Initiative’s objectives and research priorities. It directs NIH to prioritize preventable causes of maternal mortality and severe morbidity, target disparities among disproportionately affected populations, and improve care across the pregnancy continuum. The subsection also mandates an integrated approach—biological, behavioral, and other factors—and a regional evidence base, signaling NIH should fund multidisciplinary and geographically targeted work rather than only national surveillance or single‑discipline studies.
Funding mechanisms and procurement flexibility
Subsection (c) authorizes the Director to use grants, contracts, cooperative agreements, or ‘‘other transactions’’ to carry out the Initiative. Including ‘‘other transactions’’ provides flexibility to enter into nontraditional agreements (useful for rapid, industry or community partnerships) but also raises questions about oversight and standard federal grant terms. This subsection gives NIH operational flexibility to tailor funding instruments to project types—research, implementation, and evaluation.
Authorized funding level and timeframe
Subsection (d) authorizes $73,400,000 per fiscal year for 2026–2031 to implement the Initiative. This creates a multi‑year authorization ceiling that program planners can cite when designing solicitations and estimating program scale. Because the language is an authorization, actual disbursement depends on annual appropriations and any earmarking or rescissions Congress may apply.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Pregnant and postpartum people in disproportionately affected communities — the statute targets groups and regions with higher rates of maternal mortality and severe morbidity, which directs resources and tailored interventions toward those populations (e.g., many Black, Native American, rural, and low‑income communities historically experiencing worse outcomes).
- Academic and clinical researchers who study maternal health — the Initiative creates a dedicated NIH funding stream for multidisciplinary, regionally targeted studies and for translational work linking research to community interventions. That expands opportunities for centers with regional partnerships.
- Community‑based organizations and local health systems — the law explicitly funds implementation and evaluation of community interventions, creating new grant opportunities for local partners that deliver care, outreach, and supportive services and that can test practice‑based solutions in real settings.
Who Bears the Cost
- National Institutes of Health and other NIH priorities — the program’s implementation will require NIH staff time, coordination, and potentially reallocation of institute budgets to support solicitations, peer review, and program management if appropriations do not increase overall NIH funding.
- Congress and federal budget — although the bill authorizes $73.4M per year, Congress must appropriate funds; the authorization increases pressure on appropriators to provide new resources or reprogram existing ones. Appropriations decisions will determine whether the Initiative grows without crowding out other programs.
- Small community partners and health departments — while eligible for implementation funds, these organizations will face administrative and evaluation burdens to meet grant requirements, build data capacity, and sustain programs beyond grant periods if long‑term funding is uncertain.
Key Issues
The Core Tension
The bill aims to concentrate federal research dollars on equity‑focused, regionally targeted maternal health solutions while preserving flexibility to fund both rigorous science and nimble community interventions; the core tension is between speedy, locally tailored action (which favors flexible contracting and limited statutory constraints) and the need for standardized metrics, durable funding, and oversight (which demand detailed statutory guardrails and sustained appropriations). There is no easy way to achieve both maximum flexibility and maximum accountability in a short statutory text.
The statute sets broad goals and a funding ceiling but leaves many implementation choices to NIH. The law does not define key terms (for example, which populations qualify as ‘‘disproportionately affected’’ or how regions will be selected), nor does it prescribe metrics, reporting cadence, or required coordination with Medicaid, HRSA, or CDC programs that already operate maternal‑health efforts.
Those gaps give NIH flexibility to tailor the Initiative, but they also create uncertainty for applicants about eligibility, evaluation criteria, and expected outcomes.
The authority to use ‘‘other transactions’’ offers contracting agility for public‑private and community partnerships but reduces the automatic applicability of standard grant audit and reporting rules, creating oversight and transparency questions. Likewise, authorizing funds over multiple fiscal years improves planning but does not guarantee appropriations; sustained impact depends on future budget choices.
Finally, the bill directs implementation and evaluation of community interventions but does not require mechanisms for scaling successful models, aligning them with state programs (including Medicaid), or ensuring data sharing and interoperability—practical barriers that can limit the Initiative’s ability to translate findings into widespread practice.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.